Figure 7 in Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat's bone marrow cells' lysate

Figure 7. In-vivo Gene Expression Analysis: (A) represents apoptotic markers; BAX and Caspase-3, expression in treated nanostructured lipid carriers (T-NLC), treated bone marrow-derived mesenchymal stromal cells (BMSCs) lysate (C-I-BMSCs-L) and NLC loaded BMSCs lysate (C-I-NLC-BMSCs-L) groups as compared to normal (N) and carrageenan injected injury (C) groups (B) shows proinflammatory markers (IL-6 and IL-8) expression levels in treated C-I-BMSCs-L and treated C-I-NLC-BMSCs-L groups as compared to N and C groups (C) shows Proliferative markers (Ki-67, PCNA and TOP2A) expression in treated C-I-BMSCs-L and treated C-INLC-BMSCs-L group as compared to N and C groups. Whereas N-NS represents normal rats injected with normal saline, C-NS represents carrageenan-injected normal saline, C-I-DFS represents carrageenan-injected diclofenac sodium. Where; the* sign shows significance between untreated and treated groups while α and ss sign shows significance between carrageenan injury and other treatment groups. Where, ns is non-significant, * & α represents P<0.05, ** & ss represents P<0.001, *** & αss represents P<0.0001.